NCT06064877 2025-04-13
FIERCE-HN
AVEO Pharmaceuticals, Inc.
Phase 3 Recruiting
Clinical Trials
8 trialsNCT00545545 2025-03-19
Safety/Efficacy Study of Imprime PGG With Cetuximab in Patients With Recurrent/Progressive Colorectal Carcinoma
HiberCell, Inc.
Phase 1/2 Completed
NCT04464967 2021-05-12
Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers
NKGen Biotech, Inc.
Phase 1/2 Withdrawn
NCT02350712 2018-09-11
Patritumab With Cetuximab and a Platinum Containing Therapy for Patients With Head and Neck Cancer
Daiichi Sankyo
Phase 1 Completed
NCT01252628 2018-05-16
Phase 1 and 2 Study of PX-866 and Cetuximab
Seagen Inc.
Phase 1/2 Completed
NCT01309126 2017-07-13
PRIMUS
HiberCell, Inc.
Phase 3 Terminated
NCT00705016 2014-04-30
ADVANTAGE
Merck KGaA, Darmstadt, Germany
Phase 1/2 Completed
NCT00095199 2012-10-15
Docetaxel or Pemetrexed With or Without Cetuximab in Patients With Recurrent or Progressive Non-Small Cell Lung Cancer
Eli Lilly and Company
Phase 3 Completed